Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes.

Abstract

COI Statement

C. Arenillas reports grants from the CIBERONC Spanish Network during the conduct of the study. J.J. Alba-Linares reports grants from the Spanish Association Against Cancer (AECC) during the conduct of the study. T. Dwight reports grants from the National Health and Medical Research Council (Australia; APP1108032) and Hillcrest Foundation (Perpetual IMPACT Philanthropy Program) during the conduct of the study. R. Clifton-Bligh reports personal fees from Kyowa Kirin, Lilly, Specialized Therapeutics, and the Endocrine Society outside the submitted work. R. Dienstmann reports personal fees from Roche, Foundation Medicine, Guardant Health, Ipsen, Amgen, Servier, Sanofi, Libbs Farmacêutica, Merck Sharp & Dohme, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Gilead Sciences, Takeda, and Daiichi Sankyo; grants and personal fees from AstraZeneca, Merck, GlaxoSmithKline, Pfizer, and Novartis outside the submitted work; as well as investing in Trialing Health S.L. J. Capdevila reports grants and personal fees from Exelixis, Roche, Ipsen, Novartis, Eisai, and ITM; personal fees from Merck, Lilly, and Esteve during the conduct of the study; as well as grants from AstraZeneca and Gilead. J. Favier reports grants from Ligue contre le Cancer, the Association Surrénales, and the Institut National du Cancer during the conduct of the study. P. Nuciforo reports personal fees from Discovery Life Sciences outside the submitted work. N. Bechmann reports grants from the German Research Foundation during the conduct of the study. P.L.M. Dahia reports grants from the NIH/NIGMS, NIH/NCI, NETRF, VHL Alliance, and Paradifference Foundation outside the submitted work; as well as other support from holding the Robert Tucker Hayes Distinguished Chair in Oncology during the conduct of the study. R.A. Toledo reports grants from the Paradifference Foundation, the Pheipas Patients Association, the Foundation for Oncological Studies and Research (FERO), the Banco Bilbao Vizcaya Argentaria (BBVA) Foundation, AstraZeneca, BeiGene Pharmaceuticals, Novartis, La Caixa Foundation, and the Agency for Management of University and Research Grants (AGAUR) outside the submitted work; grants and personal fees from the Institute of Health Carlos III (ISCIII) of the Ministry of Economy and Competitiveness from the Spanish government; nonfinancial support from the European Network for the Study of Adrenal Tumors (ENS@T); other support from COST Action CA20122 Harmonisation, the State Research Agency (Agencia Estatal de Investigación), the Cellex Foundation, the CERCA Programme from the Generalitat de Catalunya, and other support from Personalis, Inc.; as well as, nonfinancial support from the CIBERONC Spanish Network during the conduct of the study. No disclosures were reported by the other authors.

References:

• Luo G, Ono S, Beukes NJ, Wang DT, Xie S, Summons RE. Rapid oxygenation of Earth’s atmosphere 2.33 billion years ago. Sci Adv 2016;2:e1600134.
• Gray MW. Mitochondrial evolution. Cold Spring Harb Perspect Biol 2012;4:a011403.
• Chandel NS. Evolution of mitochondria as signaling organelles. Cell Metab 2015;22:204–6.
• Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 2020;11:102.
• Semenza GL. HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001;107:1–3.